ADA 2026: Fewer deaths and clots observed with GLP‑1s in obesity with autoimmune disease

Clinical Takeaway: Consider GLP‑1 receptor agonists in patients with obesity and autoimmune disease when clinically appropriate; real-world evidence suggests meaningful reductions in thromboembolic events, ED utilization, and mortality in this high-risk group.

Adults with both obesity and autoimmune disease are at particularly high risk for cardiovascular and thrombotic complications, driven by overlapping metabolic and inflammatory pathways.

Investigators analyzed US electronic health record data from 26,408 adults with obesity (mean BMI ~37 kg/m²) and at least one autoimmune disease (including rheumatologic, endocrine, gastrointestinal, and systemic conditions). About 73% were women, with a mean age of 55 years. Patients treated with GLP‑1 receptor agonists were matched to similar patients not receiving these agents.

GLP‑1 therapy was associated with lower risk of several key outcomes compared with nonuse. Patients receiving treatment had a 44% lower risk of all-cause mortality, along with a 31% lower risk of pulmonary embolism and a 17% lower risk of venous thromboembolism. Emergency department visits were also 21% less frequent. Stroke risk showed a modest reduction, while myocardial infarction and coronary revascularization weren't significantly different.

The greater effect on venous thromboembolic events—rather than arterial outcomes—aligns with the inflammatory and hypercoagulable biology of this population. GLP‑1 agents may provide benefit through combined metabolic, anti-inflammatory, and possibly antithrombotic mechanisms.

“The 44% reduction in all-cause mortality observed among patients with obesity and co-occurring autoimmune disease is a striking finding that demands our attention,” said Fatima Cody Stanford, MD, of Massachusetts General Hospital and Harvard Medical School. “As an obesity medicine physician scientist who regularly cares for patients with complex inflammatory conditions, this study reinforces what many of us have suspected clinically—that the benefits of GLP-1 receptor agonists extend well beyond blood sugar control and weight loss and may fundamentally alter the disease trajectory for some of our highest-risk patients.”

Source: Dai H, et al. 2026 June 6. J Am Heart Assoc. Glucagon‐Like Peptide‐1 Receptor Agonists and Cardiovascular Events in Adults With Obesity and Autoimmune Disease: A Target Trial Emulation